ÂÜÀòÂÒÂ×

Evisa’s Flare Characteristics: Commitment to excellence and an eagerness to learn.

Evisa leads the scientific and technical oversight for Flare’s precision medicine-based biomarker strategy. She brings a comprehensive understanding of the oncology space with patient-forward knowledge of the drug-discovery landscape. Her work will support the rapid advancement of novel assets to development candidates, and ultimately, an accelerated path to the clinic.

Throughout her career, Evisa has been a scientific leader in translational medicine, with a strong background in solid-tumor and hematological oncology as well as immuno-oncology. She has built and led research teams that developed novel hypotheses to support forward and reverse translation and biomarker discovery across many clinical studies, cancer indications, and combinatorial therapies.

When at Dana-Farber, Evisa co-led the Harmonization of the Chromogenic Immunohistochemistry and Multiplex IF Standard Operation Procedures (SOPs) with the Cancer Immune Monitoring and Analysis Centers (CIMAC). This ongoing project provides comprehensive, standardized, and cutting-edge immune monitoring analysis for biomarker discovery and clinical deployment.